Agents targeting HIF-1α signaling such as EZN-2968 (HIF-1α antisense mRNA) and PX-478 (small molecule inhibitor of HIF-1α) have been effective treatments for advanced solid tumors and lymphoma in phase I clinical trials (Jeong et al., 2014; Welsh et al., 2004). This evidence concerns the gene HIF1A and lymphoma.